The new era of clinical trials begins with a simple question:
What does the patient feel?
Because when patients are heard and supported, trials become more engaging, retention improves, and data quality rises.
Patientverse is a European HealthTech company dedicated to transforming clinical trials into truly patient-centered experiences.
Founded with the vision of bridging the gap between complex study protocols and the everyday reality of participants, we design solutions that are human, engaging, and compliant with the highest global standards.
We operate under the GDPR framework and align with HIPAA, ICH-GCP, and national data-protection laws, ensuring full compliance wherever our technology is deployed.
Our flagship product, MyJourney, empowers patients by turning trial timelines into simple, visual pathways, enabling loved ones to accompany participants, and capturing the patient’s voice through anonymized feedback. Powered by artificial intelligence, MyJourney translates complex study data into clear, actionable insights — improving patient engagement while delivering blinded, structured outputs for sponsors and CROs.
For sponsors and CROs, we provide blinded insights on adherence, retention, and patient experience, helping improve trial quality and outcomes worldwide.
We believe that empowering patients ultimately empowers research itself.
Because well-conducted trials don’t just produce good data — they create meaningful patient experiences.
Compliance by design
Patientverse is headquartered in the European Union and operates under the GDPR framework. Our technology aligns with HIPAA, ICH-GCP, and national data-protection laws, ensuring that sponsors and CROs can deploy MyJourney with full confidence.
We follow principles of data minimization, pseudonymization, and privacy by design. All data are encrypted in transit and at rest, and our mobile development adheres to OWASP MASVS/MSTG standards.
This commitment means every feature of MyJourney is built to protect patients while delivering reliable, compliant insights to sponsors.